phosphatidylcholines has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, Y; Huang, H; Niu, Y; Quan, C; Wang, L; Wen, S; Zhang, J | 1 |
1 other study(ies) available for phosphatidylcholines and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Topics: Androgen Antagonists; Androgens; Animals; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Choline Kinase; Chromatin Immunoprecipitation Sequencing; Diacylglycerol Cholinephosphotransferase; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Phosphatidylcholines; Prostate; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Long Noncoding; Signal Transduction; Transcription Factors; Transcription, Genetic; Xenograft Model Antitumor Assays | 2020 |